Therefore, research needs to further explore the role of NOX4 in PC progression and chemotherapy resistance, so that clinic can make individual treatment for PC patients to enhance drug efficacy, extending patient survival, and improve quality of life. This evidence concerns the gene NOX4 and pachyonychia congenita.